AbbVie Bets $710 Million on AI-Designed Drugs as Nvidia-Backed Startup Eyes Public Markets
Iambic Therapeutics secures pharma giant partnership and files for IPO in same-day move that tests whether artificial intelligence can deliver on drug discovery promises.
Pharma's Computational Arms Race Heats Up as Bristol Myers Squibb Builds Supercomputing Drug Discovery Powerhouse
Bristol Myers Squibb partners with Nvidia to deploy what it claims will be the life sciences industry's most powerful AI infrastructure, signaling an escalating battle for computational supremacy in drug development.
Why the FDA Is Betting on Biology-Driven AI to Fix Drug Development's $2 Billion Failure Problem
Mechanistic AI that explains *why* drugs work—rather than just predicting outcomes—could finally give regulators the transparency needed to accelerate drug development and reduce catastrophic trial failures.
What Healthcare AI Can Learn From Vertical AI in Construction
The health AI industry's most durable companies will be those that go deepest in a single clinical domain — not the ones that build the most general-purpose platform. The success of vertical AI in adjacent industries offers a clear template.
Recursion Pharmaceuticals Advances Three AI-Discovered Drug Candidates Into Phase 2 Trials
Recursion Pharmaceuticals has announced that three drug candidates identified through its AI-powered drug discovery platform have advanced into Phase 2 clinical trials, marking a significant milestone for the AI-native pharmaceutical development model.